Insulin-like Growth Factor Deficiency

• CLINICAL_TRIALS research · 2026-02-06
  Clinical Trial Update: Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

  A global patient registry is being established to monitor long-term safety and effectiveness of Increlex (mecasermin) in children and adoles…

• FDA approval · 2023-10-20
  FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

  The FDA approved a supplemental application for INCRELEX (mecasermin) filed by Ipsen Biopharmaceuticals, Inc., resulting in labeling changes…

• CLINICAL_TRIALS trial_result · 2015-12-15
  Clinical Trial Update: rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency [Phase 2]

  Phase 2 trial investigating rhGH and rhIGF-1 combination therapy for short stature associated with IGF-1 deficiency; study terminated with r…

• FDA approval · 2012-06-14
  FDA Approved: INCRELEX — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

  FDA approved a supplemental application for INCRELEX (mecasermin) from Ipsen Biopharmaceuticals, reflecting regulatory action for this produ…

• CLINICAL_TRIALS trial_result · 2010-04-30
  Clinical Trial Update: Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency [Phase 3]

  A Phase 3 trial in prepubertal children with growth failure due to primary IGF-1 deficiency has completed with results posted.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2010-04-15
  Clinical Trial Update: Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency [Phase 2, Phase 3]

  Phase 2/3 clinical trial of recombinant human IGF-1 for short stature due to IGF-1 deficiency has completed with results posted.